https://egtc.nl/antisense-oligonucleotides-in-therapy-for-neurodegenerative-disorders/2025-02-04T22:22:20+01:00https://egtc.nl/aav5-mihtt-gene-therapy-demonstrates-broad-distribution-and-strong-human-mutant-huntingtin-lowering-in-a-huntingtons-disease-minipig-model/2025-02-04T22:22:20+01:00https://egtc.nl/development-of-an-aav-based-microrna-gene-therapy-to-treat-machado-joseph-disease/2025-02-04T22:22:20+01:00https://egtc.nl/cerebral-organoids-a-human-model-for-aav-capsid-selection-and-therapeutic-transgene-efficacy-in-the-brain/2025-02-04T22:22:20+01:00https://egtc.nl/rescue-of-spinal-muscular-atrophy-mouse-models-with-aav9-exon-specific-u1-snrna/2025-02-04T22:22:20+01:00https://egtc.nl/preclinical-efficacy-and-safety-of-adeno-associated-virus-5-alpha-galactosidase-a-gene-therapy-for-fabry-disease/2025-02-04T22:22:20+01:00https://egtc.nl/a006-splicing-dysregulation-is-a-common-theme-across-huntingtons-disease-mouse-models-and-can-be-rescued-by-huntingtin-lowering/2025-02-04T22:22:20+01:00https://egtc.nl/exon-1-targeting-mirna-reduces-the-pathogenic-exon-1-htt-protein-in-huntington-disease-models/2025-02-04T22:22:20+01:00https://egtc.nl/aav5-mihtt-mediated-huntingtin-lowering-improves-brain-health-in-a-huntingtons-disease-mouse-model/2025-02-04T22:22:20+01:00https://egtc.nl/enterovirus-d68-infection-in-human-primary-airway-and-brain-organoids-no-additional-role-for-heparan-sulfate-binding-for-neurotropism/2025-02-04T22:22:20+01:00https://egtc.nl/i04-aav5-mihtt-gene-therapy-mediates-sustained-mutant-huntingtin-lowering-in-brain-and-cerebrospinal-fluid-of-huntington-disease-minipigs-up-to-4-years/2025-02-04T22:22:20+01:00https://egtc.nl/emerging-therapies-for-huntingtons-disease-focus-on-n-terminal-huntingtin-and-huntingtin-exon-1/2025-02-04T22:22:20+01:00https://egtc.nl/human-brain-organoids-as-models-for-central-nervous-system-viral-infection/2025-02-04T22:22:20+01:00https://egtc.nl/mirna-mediated-knockdown-of-atxn3-alleviates-molecular-disease-hallmarks-in-a-mouse-model-for-spinocerebellar-ataxia-type-3/2025-02-04T22:22:20+01:00https://egtc.nl/transduction-profiles-in-minipig-following-mri-guided-delivery-of-aav-5-into-thalamic-and-corona-radiata-areas/2025-02-04T22:22:20+01:00https://egtc.nl/widespread-and-sustained-target-engagement-in-huntingtons-disease-minipigs-upon-intrastriatal-microrna-based-gene-therapy/2025-02-04T22:22:20+01:00https://egtc.nl/secreted-therapeutics-monitoring-durability-of-microrna-based-gene-therapies-in-the-central-nervous-system/2025-02-04T22:22:20+01:00https://egtc.nl/intrastriatal-administration-of-aav5-mihtt-in-non-human-primates-and-rats-is-well-tolerated-and-results-in-mihtt-transgene-expression-in-key-areas-of-huntington-disease-pathology/2025-02-04T22:22:20+01:00https://egtc.nl/a-perspective-on-organoids-for-virology-research/2025-02-04T22:22:20+01:00https://egtc.nl/aav5-mihtt-gene-therapy-for-huntington-disease-lowering-both-huntingtins/2025-02-04T22:22:20+01:00https://egtc.nl/development-of-an-aav5-based-gene-therapy-for-fabry-disease/2025-02-04T22:22:20+01:00https://egtc.nl/potent-and-sustained-huntingtin-lowering-via-aav5-encoding-mirna-preserves-striatal-volume-and-cognitive-function-in-a-humanized-mouse-model-of-huntington-disease/2025-02-04T22:22:20+01:00https://egtc.nl/aav5-mihtt-lowers-huntingtin-mrna-and-protein-without-off-target-effects-in-patient-derived-neuronal-cultures-and-astrocytes/2025-02-04T22:22:20+01:00https://egtc.nl/the-biodistribution-and-tolerability-of-raav5-mihtt-after-bilateral-intra-striatal-delivery-to-non-human-primates-s16-006/2025-02-04T22:22:20+01:00https://egtc.nl/mri-volumetric-analysis-of-20-early-manifest-huntington-disease-patients-to-determine-the-safety-of-delivering-gene-therapy-to-the-striatum-p1-8-048/2025-02-04T22:22:20+01:00https://egtc.nl/document-s2-article-plus-supplemental-information/2025-02-04T22:22:20+01:00https://egtc.nl/document-s1-figures-s1-s5/2025-02-04T22:22:20+01:00https://egtc.nl/artificial-micrornas-targeting-c9orf72-have-the-potential-to-reduce-accumulation-of-the-intra-nuclear-transcripts-in-als-and-ftd-patients/2025-02-04T22:22:20+01:00https://egtc.nl/aav5-mihtt-gene-therapy-demonstrates-sustained-huntingtin-lowering-and-functional-improvement-in-huntington-disease-mouse-models/2025-02-04T22:22:20+01:00https://egtc.nl/document-s1-figures-s1-s3-and-table-s1/2025-02-04T22:22:20+01:00https://egtc.nl/targeting-rna-mediated-toxicity-in-c9orf72-als-ftd-by-rnai-based-gene-therapy/2025-02-04T22:22:20+01:00https://egtc.nl/document-s1-figures-s1-s3-and-tables-s1-and-s2/2025-02-04T22:22:20+01:00https://egtc.nl/transcriptional-profiling-and-biomarker-identification-reveal-tissue-specific-effects-of-expanded-ataxin-3-in-a-spinocerebellar-ataxia-type-3-mouse-model/2025-02-04T22:22:20+01:00https://egtc.nl/treating-pigs-with-a-gene-therapy-for-huntingtons-disease/2025-02-04T22:22:20+01:00https://egtc.nl/i04-aav5-mihtt-gene-therapy-demonstrates-broad-distribution-and-strong-human-mutant-huntingtin-lowering-in-a-huntington-disease-minipig-model/2025-02-04T22:22:20+01:00https://egtc.nl/a07-a-comparative-study-on-blood-and-brain-hd-signatures-comparing-mouse-and-human-hd-gene-expression-data/2025-02-04T22:22:20+01:00https://egtc.nl/i05-sustained-mutant-huntingtin-lowering-in-the-brain-and-cerebrospinal-fluid-of-huntington-disease-minipigs-mediated-by-aav5-mihtt-gene-therapy/2025-02-04T22:22:20+01:00https://egtc.nl/i06-efficacy-and-safety-of-aav5-mihtt-in-hd-patient-derived-neurons/2025-02-04T22:22:20+01:00https://egtc.nl/supplementary-material-2/2025-02-04T22:22:21+01:00https://egtc.nl/supplementary-material-3/2025-02-04T22:22:21+01:00https://egtc.nl/supplementary-material-7/2025-02-04T22:22:21+01:00https://egtc.nl/supplementary-material-6/2025-02-04T22:22:21+01:00https://egtc.nl/supplementary-material-1/2025-02-04T22:22:21+01:00https://egtc.nl/supplementary-material-5/2025-02-04T22:22:21+01:00https://egtc.nl/supplementary-material-9/2025-02-04T22:22:21+01:00https://egtc.nl/supplementary-material-4/2025-02-04T22:22:21+01:00https://egtc.nl/supplementary-material-10/2025-02-04T22:22:21+01:00https://egtc.nl/supplementary-material-8/2025-02-04T22:22:21+01:00https://egtc.nl/supplementary-material-11/2025-02-04T22:22:21+01:00https://egtc.nl/translation-of-microrna-based-huntingtin-lowering-therapies-from-preclinical-studies-to-the-clinic/2025-02-04T22:22:21+01:00https://egtc.nl/supplementary-information/2025-02-04T22:22:21+01:00https://egtc.nl/aav5-mihtt-gene-therapy-demonstrates-suppression-of-mutant-huntingtin-aggregation-and-neuronal-dysfunction-in-a-rat-model-of-huntingtons-disease/2025-02-04T22:22:21+01:00https://egtc.nl/in-vivo-proof-of-concept-of-removal-of-the-huntingtin-caspase-cleavage-motif-encoding-exon-12-approach-in-the-yac128-mouse-model-of-huntingtons-disease/2025-02-04T22:22:21+01:00https://egtc.nl/l5-pre-clinical-evaluation-of-aav5-mihtt-gene-therapy-of-huntingtons-disease-in-rodents/2025-02-04T22:22:21+01:00https://egtc.nl/l4-sustained-and-strong-htt-silencing-by-aav5-mihtt-as-therapy-for-huntingtons-disease/2025-02-04T22:22:21+01:00https://egtc.nl/b03-making-anti-sense-out-of-huntingtin-levels-in-huntington-disease/2025-02-04T22:22:21+01:00https://egtc.nl/m04-preventing-formation-of-toxic-n-terminal-huntingtin-fragments-through-antisense-oligonucleotide-mediated-protein-modification/2025-02-04T22:22:21+01:00https://egtc.nl/preventing-formation-of-toxic-n-terminal-huntingtin-fragments-through-antisense-oligonucleotide-mediated-protein-modification/2025-02-04T22:22:21+01:00https://egtc.nl/ataxin-3-protein-and-rna-toxicity-in-spinocerebellar-ataxia-type-3-current-insights-and-emerging-therapeutic-strategies/2025-02-04T22:22:21+01:00https://egtc.nl/ataxin-3-protein-modification-as-a-treatment-strategy-for-spinocerebellar-ataxia-type-3-removal-of-the-cag-containing-exon/2025-02-04T22:22:21+01:00https://egtc.nl/p01-antisense-oligonucleotide-mediated-transcript-reduction-and-modulation-the-european-approach-to-develop-a-therapy-for-huntington-disease/2025-02-04T22:22:21+01:00https://egtc.nl/p03-reducing-toxic-n-terminal-huntingtin-fragments-in-hd-using-exon-skipping/2025-02-04T22:22:21+01:00https://egtc.nl/antisense-oligonucleotides-as-molecular-tools-to-silence-prolonged-cagn-tracts-in-huntingtons-disease/2025-02-04T22:22:21+01:00https://egtc.nl/ameliorating-huntingtons-disease-by-targeting-huntingtin-mrna/2025-02-04T22:22:21+01:00https://egtc.nl/biology-of-cardiac-sodium-channel-na-v1-5-expression/2025-02-04T22:22:21+01:00https://egtc.nl/antisense-based-exon-skipping-as-a-therapy-for-duchenne-muscular-dystrophy-status-and-prospects/2025-02-04T22:22:21+01:00https://egtc.nl/table-s1/2025-02-04T22:22:21+01:00https://egtc.nl/targeting-several-cag-expansion-diseases-by-a-single-antisense-oligonucleotide/2025-02-04T22:22:21+01:00https://egtc.nl/antisense-mediated-rna-targeting-versatile-and-expedient-genetic-manipulation-in-the-brain/2025-02-04T22:22:21+01:00https://egtc.nl/one-antisense-oligonucleotide-as-a-potential-therapy-for-polyglutamine-disorders/2025-02-04T22:22:21+01:00https://egtc.nl/reduction-of-prolonged-cag-repeat-containing-alleles-in-huntingtons-disease-using-antisense-oligonucleotides/2025-02-04T22:22:21+01:00https://egtc.nl/o01-an-overview-of-rna-therapeutics/2025-02-04T22:22:21+01:00https://egtc.nl/a-unique-residue-in-rab3c-determines-the-interaction-with-novel-binding-protein-zwint-1/2025-02-04T22:22:21+01:00